Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KRYSTAL BIOTECH, INC.

(KRYS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Krystal Biotech Announces $10 Million Private Placement with Frazier Healthcare Partners

08/16/2018 | 07:17pm EDT

PITTSBURGH, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has entered into a securities purchase agreement with Frazier Healthcare Partners for the private placement of 625,000 shares at $16 per share. The private placement will yield gross proceeds of $10 million and is expected to close on August 17, 2018, subject to the satisfaction of customary closing conditions.

“We are extremely pleased that an impressive investor like Frazier Healthcare Partners supports our efforts to become a leader in the field of dermatological diseases,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech, Inc.

Net proceeds from this offering are expected to be used to continue funding the research and development of Krystal’s pipeline product candidates.

Chardan acted as the sole placement agent in the transaction.

The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ: KRYS) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit http://www.krystalbio.com.

Forward-Looking Statements
This press release contains forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements.  Although Krystal's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Krystal, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, among others: actions by the FDA and other regulatory agencies, results and timing of current and planned clinical trials, risks related to the commercialization of our products, our ability to manufacture sufficient quantities of products for clinical trials and commercial launch, and those other risks detailed from time to time under the caption “Risk Factors” and elsewhere in Krystal Biotech's Securities and Exchange Commission (SEC) filings included in our Annual Report on Form on Form 10-K for the year ended December 31, 2017, and in future filings and reports of Krystal Biotech. The Company undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in its expectations.

INVESTOR CONTACT
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com

MEDIA CONTACT
Darren Opland
LifeSci Public Relations
darren@lifescipublicrelations.com

Source: Krystal Biotech, Inc.

 

Primary Logo


© GlobeNewswire 2018
All news about KRYSTAL BIOTECH, INC.
10/14KRYSTAL BIOTECH : Announces Virtual Presentation of Pre-clinical Data on KB408 for the Tre..
GL
10/14Krystal Biotech Announces Virtual Presentation of Pre-Clinical Data on Kb408 for the Tr..
CI
10/12KRYSTAL BIOTECH : GeneDx to Offer Free Genetic Testing for Dystrophic Epidermolysis Bullos..
MT
10/12OPKO HEALTH : Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genet..
AQ
10/12Krystal Biotech, Inc. and GeneDx, Inc. Announce Collaboration to Provide No-charge Gene..
CI
10/01Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference
GL
10/01KRYSTAL BIOTECH : to Present at the Chardan 5th Annual Genetic Medicines Conference
GL
09/29KRYSTAL BIOTECH : Wins Australia Ok for Early-Stage Trial of KB407 for Cystic Fibrosis
MT
09/29KRYSTAL BIOTECH : Receives Approval from the Human Research Ethics Committee in Australia ..
GL
09/29Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia..
CI
More news
Analyst Recommendations on KRYSTAL BIOTECH, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -69,6 M - -
Net cash 2021 339 M - -
P/E ratio 2021 -15,8x
Yield 2021 -
Capitalization 1 082 M 1 082 M -
EV / Sales 2021 -
EV / Sales 2022 2,31x
Nbr of Employees 75
Free-Float 75,4%
Chart KRYSTAL BIOTECH, INC.
Duration : Period :
Krystal Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KRYSTAL BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 48,72 $
Average target price 98,43 $
Spread / Average Target 102%
EPS Revisions
Managers and Directors
Krish S. Krishnan Chairman, President & Chief Executive Officer
George Chen Manager-Information Technology & CSV
Trevor Parry Senior Director-Scientific Affairs
Brittani Agostini Senior Manager-Clinical Operations
Stacie Oliver Clinical Affairs Scientist
Sector and Competitors
1st jan.Capi. (M$)
KRYSTAL BIOTECH, INC.-18.80%1 082
GILEAD SCIENCES, INC.16.08%84 795
BIONTECH SE203.83%59 820
WUXI APPTEC CO., LTD.29.45%57 897
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156